Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

製品コードS2680

Ibrutinib (PCI-32765)化学構造

CAS No. 936563-96-1

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 47100 あり
JPY 30200 あり
JPY 163000 あり
JPY 412000 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(411)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

製品説明 Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
ターゲット
BTK [1]
(Cell-free assay)
BLK [1]
(Cell-free assay)
Bmx [1]
(Cell-free assay)
CSK [1]
(Cell-free assay)
FGR [1]
(Cell-free assay)
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
体外試験

Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. [1] Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. [2] A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Rec1 cells NInCUJFHfW6ldHnvckBie3OjeR?= M{LjZ|IvPSEQvF2= M3y2OVYhcA>? MkXaTY5pcWKrdHnvckBw\iCOeX6gdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLlZ|Eh[2WubIOgZZQhOi53IIXNJIlv[3WkYYTl[EBnd3JiNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCvZYToc4Q> NILhVVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNlg4Pyd-MkWyNlI5Pzd:L3G+
human WSU-NHL cells MkP0R5l1d3SxeHnjxsBie3OjeR?= NG\zWIk4OiCq M2[wUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHdUXS2QSFygZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wPUDPxE1? NXLiVphWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
human SU-DHL6 cells M3;5cGN6fG:2b4jpZ:Kh[XO|YYm= M1LIXFczKGh? MknER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3UuTEiONjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW4JO69VS5? NFzvNlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
human DOHH2 cells Mlq3R5l1d3SxeHnjxsBie3OjeR?= MWS3NkBp NUDPcVZCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTE:KSEKgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NUDPxE1w NXnTSFhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 cells MYPGeY5kfGmxbjDhd5NigQ>? NXfscndKOSCq M{HXOGlvcGmkaYTpc44hd2ZiTGnOMWEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDh[pRmeiB4MDDtbY5{KGK7IGTSMWZTTVRiQYPzZZktKEmFNUC9NE4zKM7:TT6= Mm[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
human Ramos cells NXfFfFFUTnWwY4Tpc44h[XO|YYm= NUHMU|RwOSCq MkXZTY5pcWKrdHnvckBw\iCEdHugbY4hcHWvYX6gVoFud3NiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBRVENvZ3HtcYEzKHCqb4PwbI9zgWyjdHnvckBifCCWeYKxNlE4KGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{NCCLQ{WwQVE1KG6PLh?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human Pfeiffer cells NF\BcW1HfW6ldHnvckBie3OjeR?= M1PkNlczKGh? MnS0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVIZmcW[oZYKgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MjDuUU4> MoHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 cells NWPsZmVmTnWwY4Tpc44h[XO|YYm= NF;k[4wyKGh? MVnJcohq[mm2aX;uJI9nKGi3bXHuJIZ2dGxvbHXu[5RpKEKWSzDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KHW|aX7nJGZCVS2VcnP0bYRmKHCncITp[IUh[XNic4Xid5Rz[XSnIHHmeIVzKDZyIH3pcpMh[nliVGKtSnJGXCCDc4Phfg+9lCCLQ{WwQVAvPSCwTT6= NVPpT2lMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
Sf9 insect cells MXTGeY5kfGmxbjDhd5NigQ>? NI\IOJg3OCCvaX7z MXfJR|UxKD1iMD6wNFA{KM7:TR?= M1fTU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
sf9 cells NEL5NIZHfW6ldHnvckBie3OjeR?= NGnCfo5KSzVyIE2gNE4xODB|IN88US=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N|Y9N2F-
Sf9 insect cells MnTBSpVv[3Srb36gZZN{[Xl? MY[2NEBucW6| NEiwfGpKSzVyIE2gNE4xODB|NDFOwG0> MoO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO|UoRjJ5OUGyNVc2RC:jPh?=
Sf9 insect cells MXjGeY5kfGmxbjDhd5NigQ>? M370W|YxKG2rboO= NV25PYJbUUN3MDC9JFAvODByM{Sg{txO NXrPU3gxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|I6PDZpPkK4OFMzQTR4PD;hQi=>
Sf9 insect cells NUW0PFJyTnWwY4Tpc44h[XO|YYm= NHr3dog3OCCvaX7z NImyTGxKSzVyIE2gNE4xODB|NDFOwG0> NFr1TXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m1OlA{Pyd-Mke5OVYxOzd:L3G+
Sf9 cells NInIZWtHfW6ldHnvckBie3OjeR?= MUK2NEBucW6| NFPLemdKSzVyIE2gNE4xODB2IN88US=> NWrwfFlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
Sf9 cells NVeyPI0zTnWwY4Tpc44h[XO|YYm= NVzZelA4PjBibXnudy=> M1LhVmlEPTBiPTCwMlAxODVizszN NWXjcYFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
Ramos cells NVHlVpZCTnWwY4Tpc44h[XO|YYm= MkXyNUBp NGPwPXhKSzVyIE2gNE4xODB3IN88US=> NUTCc5BDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
Sf9 cells M4K5V2Z2dmO2aX;uJIF{e2G7 NEnyeVI3OCCvaX7z MnTWTWM2OCB;IECuNFAyKM7:TR?= NHXqe489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC3O|YxQCd-M{CwO|c3ODh:L3G+
Pfeiffer cells MoC3R5l1d3SxeHnjbZR6KGG|c3H5 NGSydVI4OiCq NHnyS5hIUTVyIE2gNE4xODJizszN M{nB[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
B cells M3;lUGZ2dmO2aX;uJIF{e2G7 Mly0NUBp MnrHTWM2OCB;IECuNFA1PiEQvF2= MmfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OUC5PFgoRjNyMkmwPVg5RC:jPh?=
Sf9 insect cells MmS1SpVv[3Srb36gZZN{[Xl? MVmyJJRwKDZyIH3pcpM> NVuwZ|FCU2liPTCwMlAxPDhizszN M2L0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Ramos cells NXf3WHplTnWwY4Tpc44h[XO|YYm= MV6xJIg> MX;JR|UxKD1iMD6wNFc2KM7:TR?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 insect cells M3HTTmZ2dmO2aX;uJIF{e2G7 NHLQTJo3OCCvaX7z NWn0S5gxUUN3MDC9JFAvODB6IN88US=> NV;rS|BjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
TMD8 cells M2fwOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MlvPO|IhcA>? NU[zbZNMUUN3MDC9JFAvODFizszN NIK2XGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUexOVAzOyd-Mkm3NVUxOjN:L3G+
CD19+ B cells MWTGeY5kfGmxbjDhd5NigQ>? Mln1NUBp NF3WZYNKSzVyIE2gNE4xOTJizszN NUn6d4luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVc6QDJpPkK5OFU4QTh{PD;hQi=>
Sf9 insect cells MXnGeY5kfGmxbjDhd5NigQ>? M1OwSVYxKG2rboO= M4D1T2lEPTBiPTCwMlAyOiEQvF2= NFjl[4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells Mon4SpVv[3Srb36gZZN{[Xl? MUOxJIg> NHPXXodKSzVyIE2gNE4xOTRizszN Mn7iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 insect cells Ml\USpVv[3Srb36gZZN{[Xl? NH7Vb2wyKGh? NUO0[oI5UUN3MDC9JFAvODF2NDFOwG0> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
Sf9 insect cells NW\ueXZmTnWwY4Tpc44h[XO|YYm= NFTBcFE3OCCvaX7z NWHpT|dGUUN3MDC9JFAvODF4MTFOwG0> M4W1cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
HCC827 cells MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? M4nNVlczKGh? NWjUVGJ1UUN3MDC9JFAvODN7IN88US=> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd|NEW4NUc,Ojh5M{S1PFE9N2F-
PC9 cells NHS1UoVHfW6ldHnvckBie3OjeR?= M2DJTFczKGh? NIfhXXRIUTVyIE2gNE4xPSEQvF2= M4LhU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
Sf9 cells NEHGb4RHfW6ldHnvckBie3OjeR?= NV3Hd|NVPjBibXnudy=> NV7PU4FpUUN3MDC9JFAvOSEQvF2= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
H3255 cells NGTDV3BHfW6ldHnvckBie3OjeR?= NGe2d204OiCq M2nNWGdKPTBiPTCwMlEyKM7:TR?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BaF3 cells MlzHSpVv[3Srb36gZZN{[Xl? Mo\ZO|IhcA>? MYjHTVUxKD1iMD6xNkDPxE1? Ml:1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
BAF3 cells NVPaVlMzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MUC3NkBp M3LucWdKPTBiPTCwMlEzKM7:TR?= NVTuW|RmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ|PD;hQi=>
Sf9 insect cells MUfGeY5kfGmxbjDhd5NigQ>? M3\SSFYxKG2rboO= NWj5R3M1UUN3MDC9JFAvOTJ|IN88US=> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Sf9 insect cells NFPwfoNHfW6ldHnvckBie3OjeR?= MUO2NEBucW6| MUTJR|UxKD1iMD6xOFYh|ryP NI[weXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
BAF3 cells MWnGeY5kfGmxbjDhd5NigQ>? M4DG[VczKGh? NUTaZWg6T0l3MDC9JFAvOTZizszN MkHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
Sf9 cells MWTGeY5kfGmxbjDhd5NigQ>? NFi5eJc3OCCvaX7z NWf3emNqUUN3MDC9JFAvOiEQvF2= M4XBNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
MV411 cells M{i4fmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWXHTVUxKD1iMD6yOUDPxE1? NIS0PGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
MV4-11 cells NX:3SXlxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NH60OWI4OiCq MnLNS2k2OCB;IECuN|Mh|ryP MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
MV4-11 cells MkTtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M1;3eVczKGh? NWnWfVBHT0l3MDC9JFAvOzNizszN MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
DOHH2 cells NUX3UGFDS3m2b4TvfIlkcXS7IHHzd4F6 NHvwV4M4OiCq M3foZ2dKPTBiPTCwMlQyKM7:TR?= NHfGelA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
HCC827 cells NXr4RVNqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NF3nZZg6PiCq MkT1SWM2OCB;IECuOFUh|ryP NUPWdY5ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
SU-DHL6 cells Ml7ZR5l1d3SxeHnjbZR6KGG|c3H5 M2ftTVczKGh? M2q4U2dKPTBiPTCwMlU5KM7:TR?= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
M07e cells NYT2OZQ6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVHzXVVqT0l3MDC9JFAvPTlizszN MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
NCI-H1975 cells Mne4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NIPm[5g6PiCq M3HWOGVEPTBiPTCwMlY1KM7:TR?= MlLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
SU-DHL-2 cells NEX5W|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWLGfGIyT0l3MDC9JFAvPjRizszN NFTGT4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
HEK293T cells M1ToSWZ2dmO2aX;uJIF{e2G7 NVzPOot7OSCq NXfkVpJlUUN3MDC9JFAvQSEQvF2= NI\QZXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
Ramos cells NWHXWYdbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MoHQO|IhcA>? NF;EfYlKSzVyIE2gNE46OiEQvF2= MlrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5MUWwNlMoRjJ7N{G1NFI{RC:jPh?=
BA/F3 cells Ml\JRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M3LRN|czKGh? NUjPUG5WUUN3MDC9JFEh|ryP MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
WSU-NHL cells NVfDWVdlS3m2b4TvfIlkcXS7IHHzd4F6 MV:3NkBp NWLRZ4RoT0l3MDC9JFEvODlizszN NHrKd3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
NCI-H1975 cells MoHYSpVv[3Srb36gZZN{[Xl? MlPjO|IhcA>? NW[3ZWR6T0l3MDC9JFEvOiEQvF2= MnW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975 cells NUnOcos1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M1XOR|czKGh? Ml[yTWM2OCB;IEGuNlch|ryP M2LLbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{O0OVgyLz5{OEezOFU5OTxxYU6=
Raji cells NHfqRlhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NV7FfJgyPDhiaB?= NUjITox3UUN3MDC9JFEvPDlizszN NX\SSI9pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OlczQTVpPkK5OVY4Ojl3PD;hQi=>
Pfeiffer cells M3\TT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEL1VG9IUTVyIE2gNU43KM7:TR?= NVyyXpdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
A431 cells NEDwUYdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M{fJ[Fk3KGh? MUXFR|UxKD1iMj6zPEDPxE1? M{PRclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
BAF3 cells M{nxNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MVK3NkBp M{TBSmdKPTBiPTCyMlUh|ryP MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
U937 cells MnvKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlT0S2k2OCB;IEKuPUDPxE1? MkHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
NB4 cells MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXjBPIIxT0l3MDC9JFMh|ryP NWXpWVBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
Ramos cells NILzOZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYfHTVUxKD1iMz60JO69VQ>? NYHtN2hlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
SKM1 cells NHXERpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGT0fW9IUTVyIE2gN{43KM7:TR?= MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
U2932 cells M1PNXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4K0e2dKPTBiPTC0MlQh|ryP MlXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
Ramos cells NHfhU4pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MkDCO|IhcA>? M323TmlEPTBiPTC1MlE1KM7:TR?= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
Ramos cells NXnCXoNOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MVW0PEBp Mn3FTWM2OCB;IEWuNVQh|ryP M4rVRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
Ramos cells MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MWC0PEBp M3PBVmlEPTBiPTC1Mlg5KM7:TR?= MlnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{K5OFYoRjJ6NEOyPVQ3RC:jPh?=
Ramos cells Ml7iRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MYO3NkBp Ml7tTWM2OCB;IE[uOlIh|ryP M3\JXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
K562 cells NXPmS|lESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M2nROFQ5KGh? M{fsS2lEPTBiPTC3MlUh|ryP M1zWfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5|MEC3O|YxQDxxYU6=
HL60 cells NVTacnZbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NGjpXYo1QCCq NUS1[mVqUUN3MDC9JFgh|ryP M3y3RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5|MEC3O|YxQDxxYU6=
Ramos cells MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MWe0PEBp MW\JR|UxKD1iOD6xNUDPxE1? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N|Y9N2F-
Ramos cells NHe5TVBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NFTodG81QCCq M17JVGlEPTBiPTC4MlI3KM7:TR?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV4N{K5OUc,Ojl3NkeyPVU9N2F-
OCI-AML3 cells NX7q[XZQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3fpeWdKPTBiPTC5MlIh|ryP M1jGN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
BAF3 cells MofTR5l1d3SxeHnjbZR6KGG|c3H5 MV63NkBp NXmxcpZtT0l3MDC9JFExKM7:TR?= M1riSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkOwOVU{Lz5{Nk[zNFU2OzxxYU6=
BAF3 cells M{LtO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NVr0OnZOPzJiaB?= NUftOHdbT0l3MDC9JFExKM7:TR?= M4LiblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3 cells NYDXPJQ6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXW3NkBp NFjWdm1IUTVyIE2gNVAh|ryP NVLleJVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NAMALWA cells MnvlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M3P1N|czKGh? M2fpXGlEPTBiPTCxNE41PSEQvF2= NV;XNGlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFYyOzZpPkK5NVQ3OTN4PD;hQi=>
Ramos cells MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MXO0PEBp NWnYbm5MUUN3MDC9JFEzNjZizszN M4LDbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Raji cells M4rDVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M1Hab|Q5KGh? NEPGZ5dKSzVyIE2gNVQvOiEQvF2= M{DXflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5|MEC3O|YxQDxxYU6=
Raji cells NYDGNWhDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MUC0PEBp M1LZdWlEPTBiPTCxOU4zKM7:TR?= M4\QblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M3Lz5{N{m5OFc{PjxxYU6=
MIAPaCa2 cells NVy3WGhUS3m2b4TvfIlkcXS7IHHzd4F6 M4jseVMh\GG7cx?= NV\kVpZVUUN3MDC9JFE3NjZizszN M17OWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEe3NlI5Lz5{N{C3O|IzQDxxYU6=
HeLa cells M2\4WGN6fG:2b4jpZ4l1gSCjc4PhfS=> MorIN{Bl[Xm| M17JNGlEPTBiPTCxOk45KM7:TR?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
Raji cells NF;wcY1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1;KUFQ5KGh? NUjJVlFtUUN3MDC9JFE6NjNizszN M1HNbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Raji cells MmXqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MXe0PEBp MYHJR|UxKD1iMUmuN{DPxE1? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|Mkm0Okc,Ojh2M{K5OFY9N2F-
Raji cells MnqxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? Ml;EO|IhcA>? NX;OSlVKUUN3MDC9JFE6NjVizszN NWT1UGd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
Raji cells M13BO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NInkOFI1QCCq M4TkVWlEPTBiPTCxPU42KM7:TR?= NVPHSZlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
NAMALWA cells NYjiOoxzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M3LYNVczKGh? MX;JR|UxKD1iMUmuOkDPxE1? NWPPe5A5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
A2780 cells MkTwR5l1d3SxeHnjbZR6KGG|c3H5 NXLtXIRvOyCmYYnz M3npSWVEPTBiPTCyNE4yKM7:TR?= NEC2U5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O|IzQCd-MkewO|czOjh:L3G+
Raji cells MlHFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M4H1U|czKGh? NILhcIRKSzVyIE2gNlAvQDhizszN NHfpeI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
A549 cells NGPsOFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NYHCSndsPzJiaB?= M2jhTmlEPTBiPTCyNU44QSEQvF2= Mk[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
SW480 cells M17vUWN6fG:2b4jpZ4l1gSCjc4PhfS=> M4XWVFMh\GG7cx?= MUDJR|UxKD1iMkWuOkDPxE1? NGXnZms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O|IzQCd-MkewO|czOjh:L3G+
Ramos cells Ml3UR5l1d3SxeHnjbZR6KGG|c3H5 M2nFblI1KGh? NYn5XXh2UUN3MDC9JFI5NjdizszN MmK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{N{S2O|UoRjJ6Mke0Olc2RC:jPh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
pEGFR(Tyr1068) / EGFR; 

PubMed: 28061447     


Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment.

pBTK / pPLCγ2 / pAKT / pERK / pJNK; 

PubMed: 23940282     


Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.

28061447 23940282
Immunofluorescence
CD11b; 

PubMed: 30231870     


BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm.

COX-2; 

PubMed: 30231870     


BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies. 

30231870
ELISA
hTNFα; 

PubMed: 26627823     


PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3).

IL-10; 

PubMed: 27792904     


LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.

26627823 27792904
体内試験

In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. [1] In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

- 合併

Kinase Assays :

In vitro kinase IC50 values are measured using 33P filtration binding assay after 1 hour incubation of kinase, 33P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology.
細胞試験:

[2]

- 合併
  • 細胞株: Chronic lymphocytic leukemia (CLL) cells
  • 濃度: 0.01-100 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    MTT (3'[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays are performed to determine cytotoxicity. Briefly, cells (CLL B cells or healthy volunteer T cells or NK cells) are incubated for 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD.


    (参考用のみ)
動物試験:

[1]

- 合併
  • 動物モデル: MRL-Fas(lpr) lupus model and collagen-induced arthritis model.
  • 投薬量: ≤50 mg/kg
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 88 mg/mL (199.77 mM)
Ethanol 45 mg/mL (102.15 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 440.5
化学式

C25H24N6O2

CAS No. 936563-96-1
Storage powder
in solvent
別名 N/A
Smiles C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04294641 Recruiting Drug: Ibrutinib Chronic GVHD National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 5 2021 Phase 2
NCT04665115 Not yet recruiting Drug: Ibrutinib|Other: Quality-of-Life Assessment Asymptomatic COVID-19 Infection Laboratory-Confirmed|B-Cell Neoplasm|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Symptomatic COVID-19 Infection Laboratory-Confirmed|Waldenstrom Macroglobulinemia Academic and Community Cancer Research United|National Cancer Institute (NCI) December 31 2020 Phase 2
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How to reconstitute the compound S2680 for in vivo studies?

  • 回答:

    For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Tags: Ibrutinib (PCI-32765)を買う | Ibrutinib (PCI-32765) ic50 | Ibrutinib (PCI-32765)供給者 | Ibrutinib (PCI-32765)を購入する | Ibrutinib (PCI-32765)費用 | Ibrutinib (PCI-32765)生産者 | オーダーIbrutinib (PCI-32765) | Ibrutinib (PCI-32765)化学構造 | Ibrutinib (PCI-32765)分子量 | Ibrutinib (PCI-32765)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID